LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity PipelineVANCOUVER, WA / ACCESS Newswire / July 16, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a services agreement with Oxygen Handel GmbH ("OH"), a specialized preclinical and regulatory development organization, to initiate Phase 0 strategic development planning for the Company's transdermal metabolic therapeutics pipeline.
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and TirzepatideVANCOUVER, BC / ACCESS Newswire / June 17, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion of its comparative mouse study (the "Study") evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies1. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules.
